Quoin Pharmaceuticals Ltd. announced positive interim results from its clinical study of QRX003 for treating Pediatric Netherton Syndrome, showing significant improvements in skin appearance.
Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” to “Mild” after 6 ...
Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label Study ...
Quoin Pharmaceuticals, Inc. ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical ...
ASHBURN, Va., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty ...
Quoin Pharmaceuticals Ltd. announced positive interim clinical data from an ongoing study of QRX003 for Netherton Syndrome, highlighting significant improvements in skin condition and patient ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan ...
Quoin Pharmaceuticals (QNRX) announces interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study. The ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan ...
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback